Browse Articles
Discover research articles across all indexed journals
Acid‐Triggered, Enzyme‐Enabled EPS‐Degrading Nanoplatform With Enhanced In Situ Retention for Intravenous Biofilm Therapy
ABSTRACT Bacterial biofilms present a major challenge to antibacterial therapy due to their dense extracellular polymeric substance (EPS) matrix, which limits nanoparticle penetration and reduces drug efficacy. Here, we report a pH‐responsive, surface charge‐adaptive multifunctional nanosystem (DA‐L@DTTB/Bro) for efficient in vivo treatment of biofilm‐associated infections. The nanosystem integrates pH‐triggered charge adaptation, in situ self‐aggregation, photothermal responsiveness, enzymatic EPS degradation, and NIR‐II imaging. Cationic phospholipid AGPDP, together with cholesterol and thermosensitive DPPC, self‐assembled into liposomes encapsulating bromelain in the hydrophilic core and an NIR‐II‐emissive photothermal agent (DTTB) in the hydrophobic layer. Surface modification with DA‐functionalized chitosan (CS‐DA) generates negatively charged nanoparticles for prolonged circulation. At acidic infection sites, DA hydrolysis restores the cationic surface, enhancing biofilm penetration, while residual CS‐DA induces self‐aggregation to improve retention. NIR irradiation triggers DTTB‐mediated hyperthermia, directly killing bacteria and disassembling liposomes to release bromelain, which degrades EPSs and facilitates biofilm dispersion. The nanosystem eradicates methicillin‐resistant Staphylococcus aureus biofilms in vitro with 99.99% efficiency, enables high‐contrast NIR‐II imaging, persists at abscess sites in vivo, and accelerates wound healing. Furthermore, it demonstrates effective therapeutic activity against biofilm‐associated infections in deep pulmonary tissues. This study presents a versatile intravenous strategy for targeted, synergistic therapy against biofilm‐associated infections in vivo.
Fabrication of Mechanically Reinforced Photo‐Cross‐linked Hydrogels with Steep Post‐Gelation Threshold Curing via Vinylated Self‐Assembling Peptides
ABSTRACT Tomographic volumetric 3D printing (TVP) enables the ultrafast, layer‐free fabrication of hydrogel devices. However, its widespread application is hindered by insufficient curing within the narrow light‐dose processing window, which ultimately compromises the fidelity and stability of the printed hydrogels. To address this challenge, we introduce a peptide self‐assembly‐mediated polymerization strategy to engineer mechanically reinforced hydrogels that exhibit steep curing immediately following the gelation threshold. In our approach, vinylated self‐assembling peptides (vSAPs) are conjugated to tetra‐arm polyethylene glycol macromers (vSAP‐macromers). The self‐assembly of vSAP‐macromers induces nanoscale spatial confinement of vinyl groups, which substantially shortens the diffusion distance for radical propagation. Consequently, vSAP‐macromers exhibit steep conversion and rapid network formation once the light dose exceeds the polymerization threshold. Moreover, the incorporation of vSAPs induces a potential nanoreinforced network, leading to substantial mechanical reinforcement. Owing to these features, vSAP‐macromers ensure the in‐process stability of hydrogel constructs under restricted light doses. Consequently, this leads to improvements in both the printing fidelity and mechanical performance of the final TVP‐fabricated hydrogels. Collectively, this work offers a generalizable design framework for tailoring high‐performance hydrogels for TVP and a solution to resolve the polymerization kinetic mismatch in hydrogel volumetric printing.
Functional characterization of UHRF1 variants in facilitating DNA methylation
AI-assisted colonoscopy and detection/miss of adenomas and sessile serrated lesions: An updated systematic review and meta-analysis.
4 Background: AI-assisted colonoscopy may improve real-time lesion recognition across multiple quality indicators, including adenoma detection rate (ADR), miss rates, and sessile serrated lesion (SSL) outcomes. Additional trials and endpoints have emerged since prior syntheses, warranting an updated estimate. Methods: PubMed, Scopus, Embase, and the Cochrane Library were searched from inception through 8 January 2026 for studies comparing AI-assisted versus standard colonoscopy. Prespecified outcomes were adenomas per colonoscopy (APC), ADR, adenoma miss rate, SSL detection rate, and SSL miss rate. Two reviewers independently screened and extracted data. Effects were pooled as RRs (dichotomous) or MDs (continuous) with 95% CIs using random-effects models, with fixed-effect models as sensitivity analyses. Heterogeneity was assessed by I², τ², and Q; robustness by leave-one-out, influence diagnostics (Baujat/radial/GOSH), and funnel plots. Results: Twenty-eight studies (N=27,188; AI n=13,393, control n=13,795) were included. ADR improved with AI assistance (28 studies; RE RR 1.19, 95% CI 1.13–1.25; I²=66.6%), including among expert endoscopists (9 studies; n=8,866; RE RR 1.17, 95% CI 1.09–1.25; I²=37.4%). Adenoma miss rate was lower with AI (6 studies; n=2,096 adenomas; RE RR 0.45, 95% CI 0.37–0.54; I²=14.8%). SSL detection improved (19 studies; n=20,603; RE RR 1.15, 95% CI 1.01–1.31; I²=41.8%). APC showed no significant difference (21 studies; n=18,839; RE MD 0.14, 95% CI −0.05 to 0.32; I²=98.6%), with discordant fixed-effect results (MD −0.16, 95% CI −0.19 to −0.12). SSL miss rate evidence was imprecise (4 studies; 107 SSLs; RE RR 0.47, 95% CI 0.15–1.48; I²=65.4%). Influence diagnostics and GOSH analyses confirmed robustness of primary estimates; funnel plots indicated outliers in sparse outcomes. Conclusions: AI-assisted colonoscopy improved ADR, adenoma miss rate, and SSL detection, including among expert endoscopists. SSL miss rate evidence remains limited to 4 studies with sparse events. Further trials are needed to clarify variability across platforms and settings.
Clinical characteristics and mutation status of KRAS, NRAS, and BRAF genes in stage IV colorectal cancer patients at Hanoi Medical University Hospital.
149 Background: RAS and BRAF mutations play an important role in treatment selection and prognosis in metastatic colorectal cancer (mCRC). However, data on their clinical associations in Vietnamese patients remain limited. Objectives: To describe the clinical and subclinical characteristics and determine the mutation status of KRAS, NRAS, and BRAF genes in patients with stage IV colorectal cancer at Hanoi Medical University Hospital, and to explore their associations with selected clinical factors. Methods: This retrospective descriptive study included 144 patients with metastatic colorectal cancer and available KRAS, NRAS, and BRAF mutation results, treated between June 2023 and June 2025. Clinical, laboratory, and metastatic characteristics were collected and analyzed. Associations between mutation status and clinical variables were evaluated using appropriate statistical tests. Results: The mean age was 59.1 ± 13.5 years. Mutation rates were 39.6% for KRAS, 2.1% for NRAS, and 3.5% for BRAF, with 45.1% of patients harboring at least one RAS/BRAF mutation. KRAS mutation was significantly associated with right-sided primary tumors, tumor-related complications, elevated serum CEA (>20 ng/mL), bone metastasis, and more than five metastatic sites (all p < 0.05). No significant associations were observed between KRAS mutation and age, sex, ECOG performance status, histologic features, MSI status, or other metastatic characteristics. NRAS and BRAF mutations were not significantly associated with any evaluated clinical or paraclinical factors. Conclusions: KRAS mutation was identified in a substantial proportion of patients and was significantly associated with several adverse clinical features. These findings highlight the importance of routine molecular testing to support personalized treatment strategies in metastatic colorectal cancer.
Publisher Correction: Divergent multifunctional P450s-empowered biosynthesis of bioactive tripterifordin and cryptic atiserenoids in Aconitum implies convergent evolution
Initiating Photocontrolled Atom Transfer Radical Polymerization from a Redox-Activated Functional Group
Recognition of specific amino acids in migratory rivers and daily rhythmic behavior of naked carp (Gymnocypris przewalskii)
Abstract Gymnocypris przewalskii is an endemic migratory fish in the high-altitude, saline-alkaline Lake Qinghai. This study investigated whether L-serine (Ser) acts as a chemical cue guiding its migration. Water analysis revealed significantly higher concentrations of Ser in migratory rivers than in the lake, where phenylalanine (Phe) dominated. In behavioral experiments, G. przewalskii exhibited a significant preference for Ser-enriched water during the daytime (10:00, 15:00, 18:00), spending 63% to 74% of the time in the Ser chamber, while their preference for Ser diminished at night (21:00), where the time spent in the Ser chamber was only 34%. Additionally, G. przewalskii showed significantly lower instantaneous swimming speeds and reduced turning frequencies in the Ser-enriched water compared to the control group, indicating a more stable behavioral pattern. Furthermore, continuous monitoring revealed that the migration frequency of G. przewalskii during the daytime was significantly higher than at night, suggesting that light conditions may interact with chemical cues to regulate their migratory behavior. This study provides evidence of significant differences in the amino acid composition between the lake water and the migratory rivers of Lake Qinghai, as well as G. przewalskii ’s preference for Ser in the migratory rivers. It also highlights the distinct diel rhythmicity in their migratory behavior, offering valuable scientific insights for understanding the adaptive mechanisms of saline-alkaline fish species. These findings also have important implications for the conservation of the Lake Qinghai ecosystem.
Nanodiamonds made from tiny graphene triangles
Coordination Compensation Stabilization of Monodentate‐Ligand Copper‐Iodide Hybrids for Efficient Light‐Emitting Diodes With Record‐High External Quantum Efficiency Above 20%
ABSTRACT Copper–iodide hybrids have emerged as promising candidates for eco‐friendly light‐emitting diodes (LEDs). Although high‐efficiency LEDs based on multidentate‐ligand copper–iodide hybrids have been reported, those utilizing monodentate‐ligand ones remain challenges because their surface ligands are prone to dissociation, producing exposed Cu + ions that induce non‐radiative recombination. Herein, we propose a coordination compensation stabilization strategy to achieve efficient monodentate‐ligand copper–iodide LEDs by incorporating pyridine‐terminated semiconducting molecules. We demonstrate that the strong electron‐withdrawing moieties of pyridine are integrated to stabilize Cu 4 I 4 core by increasing the electron cloud density of termini contacting with cluster, which enhances the coordination with exposed Cu + ions. This strategy synergistically passivates the ionized metallic defects to reduce non‐radiative recombination and increases the carrier mobility to promote electron/hole transport within emitters. Consequently, we fabricate LEDs reaching a record‐high electroluminescence efficiency of 20.4% with an average of 19.8% over 60 devices, half‐lifetime of 1117.5 h, large‐area of 81 cm 2 , and demonstrate a broad universality applicable to various monodentate‐ligand hybrids, representing a sufficiently striking advance over existing copper‐iodide systems. The study provides a new strategy to pave the way for enhanced device performance of copper–iodide hybrid LEDs toward practical applications.
Spatiotemporal Engineering for the Synthesis of Multi‐Scale Turing‐Patterned High‐Entropy Alloys
ABSTRACT Subnanoscale alloys are recognized as innovative electrocatalysts for sustainable energy conversion systems. However, their confinement to a single‐scale framework often impedes their ability to meet the multifaceted demands of catalytic reactions. Here, we propose a spatiotemporal control strategy that leverages interfacial etching‐driven reaction‐diffusion, guided by a specific atomic self‐arrangement, for the versatile fabrication of multi‐scale Turing‐patterned alloys. These alloys, formed on three‐dimensional nanoporous metal compounds, feature sub‐2 nm stripe widths, compositions from binary to high‐entropy, and successfully overcome conventional limitations in stripe width and composition. The tunable cross‐scale structures of these materials facilitate efficient co‐production of hydrogen and benzonitrile at high current densities. This excellent performance, revealed by combined computational and experimental studies, originates from the synergy of defects, stress, and confinement effects in the Turing patterns, as well as optimal transport within the nanoporous framework. Our strategy provides a viable pathway for the cross‐scale manufacturing of functional alloys with diverse applications.
Sphingomyelin synthase 2 regulates host protection conferred by the administration of Cryptococcus neoformans Δsgl1 strain
The impact of end-of-consolidation measurable residual disease in the era of novel pediatric leukemia therapy.
259 Background: The introduction of blinatumomab (BLINA) has improved event-free survival (EFS) and overall survival (OS) in pediatric patients with high-risk B-cell acute lymphoblastic leukemia (ALL). In patients with post-induction measurable residual disease (MRD) positivity, BLINA may serve as a safe bridging therapy to hematopoietic cell transplantation (HCT). However, little is known about the impact of end-of-consolidation (EoC) MRD on outcomes in high-risk pediatric ALL in the current BLINA-incorporated treatment era. Methods: We retrospectively enrolled pediatric patients diagnosed with high-risk B-cell ALL between February 2022 and December 2024 at Chang Gung Memorial Hospital. Patients were categorized into EoC MRD-negative and EoC MRD-positive groups. Outcomes of interest included EFS, OS, and BLINA-related adverse events (AEs). Results: The cohort consisted of 15 patients. With a median follow-up of 24 months, the observed 2-year EFS and OS rates were 71.5% and 86.7%, respectively. Based on EoC MRD status, 8 patients were classified as EoC MRD-negative and 7 as EoC MRD-positive. Baseline characteristics were comparable between the two groups. Higher relapse (57.1% vs. 0%, P = 0.0256) and mortality (28.6% vs. 0%, P = 0.2) rates were observed in the EoC MRD-positive group. The 2-year EFS was significantly higher in the EoC MRD-negative group (100% vs. 42.9%, P = 0.02). No high-grade short-term or long-term BLINA-related AEs were observed in either group. Conclusions: Achieving EoC MRD negativity was associated with sustained remission and improved survival in high-risk pediatric B-cell ALL treated with early intensification chemotherapy and BLINA. EoC MRD assessment may help identify patients who can maintain disease control without HCT. Comparisons between EoC MRD-positive and EoC MRD-negative groups. EoC MRD-positive(N= 7) EoC MRD-negative(N = 8) P value Age (years) 7.1 5.4 0.3969 Sex >0.9999 Male 5 5 Female 2 3 Karyotype 0.3203 Hyperdiploidy 0 2 Adverse 2 1 Others 5 5 Molecular alterations 0.3971 ETV6::RUNX1 0 2 BCR::ABL1 1 3 PAX5-altered 1 0 ZNF384 1 1 KMT2A 1 0 No detectable alteration 3 2 Relapse events 57.1% 0% 0.0256* EFS (months) 19 22 0.3778 Survival events 71.4% 100% 0.2 OS (months) 32 22 0.9319 Abbreviations: EFS, event-free survival; EoC, end-of-consolidation; MRD, measurable residual disease; OS, overall survival; *P value <0.05.
Tofacitinib for immune-related adverse events ≥ grade 3 induced by immune checkpoint inhibitors: A single-arm, open-label, two-stage study.
81 Background: This study evaluates the efficacy and safety of tofacitinib, a JAK inhibitor, in treating irAEs and explores its feasibility as a bridging strategy to facilitate ICI resumption. Methods: We conducted a single-arm, open-label, two-stage prospective study (Simon design) (registration number: MR-35-26-014338) . Patients who developed grade ≥3 irAEs after ICI treatment at Fujian Cancer Hospital between July 2024 and February 2026, and who were refractory to glucocorticoids, glucocorticoid-dependent, or declined glucocorticoid therapy, were enrolled. Treatment regimen: Tofacitinib 5 mg orally twice daily. Outcomes assessed: irAE response rate, time to response, tumor status, and ICI rechallenge status, among others. Results: Twenty-three patients were enrolled: 13 (56.52%) in Stage 1 and 10 (43.48%) in Stage 2. Median age was 65 years. Baseline characteristics included glucocorticoid resistance (n=15, 65.22%), dependence (n=5, 21.74%), and patient refusal (n=3, 13.04%). Regarding ICI regimens, 11 (47.83%) developed irAEs from monotherapy and 12 (52.17%) from combination immunotherapy. IrAE manifestations included rash (n=16, 69.57%), arthritis (n=3, 13.04%), troponin elevation (n=2, 8.70%), esophagitis (n=1, 4.35%), and gingivitis (n=1, 4.35%). Efficacy assessment showed a 91.30% (21/23) response rate (≥one-grade improvement) for irAEs, with a median time to response of 3 days. Response rates were 87.50% for rash and 100% for all other irAEs. In terms of oncological assessment, except for 1 terminally ill patient and 2 patients with insufficient follow-up who could not be evaluated, the remaining 20 patients achieved a 100% disease stability rate within 8 weeks of tofacitinib treatment. As of the data cutoff, 14 patients had been followed up for more than 20 weeks, with a disease stability rate of 85.71%. Regarding ICI resumption, 10 patients restarted immunotherapy; 6 (60%) received concurrent tofacitinib maintenance. No irAE recurrence was observed (median follow-up 6.0 months, range 2.6–16.0 months). Patients rechallenged with ICI plus tofacitinib maintenance showed 100% disease stability at 8 weeks; among 4 with >20 weeks follow-up, stability was 75%. No tofacitinib-related adverse events, infections, or thromboembolic events occurred in either stage. Conclusions: Tofacitinib demonstrates high response rates and rapid onset for grade ≥3 irAEs that are refractory to, dependent on, or declined by patients in favor of glucocorticoids, while effectively enabling safe ICI resumption with a favorable safety profile. These findings establish tofacitinib as a promising second-line therapeutic option for immune-related adverse events. Clinical trial information: MR-35-26-014338 .
Interferon-elicited lipoprotein metabolism in lung fibroblasts facilitates premetastatic niche formation
Dynamics and Mechanism of Photoenzymatic Dehalogenation Reactions through Electron-Transfer Bifurcation
Publisher Correction: Enhancement of cauliflower (Brassica oleracea var. botrytis) water stress resistance using paclobutrazol and partial root-zone irrigation
Mysterious protein sets up a beneficial partnership between bacteria and insects
Sulfur‐Substituted SAMs Induce Pb─S Antibonding Hybridization for Efficient and Durable Perovskite‐Silicon Tandems
ABSTRACT Further improvements in tandem efficiency and long‐term operational stability critically depend on regulating the buried perovskite interface, where interfacial disorder and residual strain often dominate nonradiative losses and degradation pathways. In contrast to conventional carbazole‐based SAMs used in p–i–n architectures, the sulfur‐substituted SAM developed in this work is designed to directly interact with the perovskite lattice, enabling modulation of the local hybridization at the buried interface. Here we demonstrate that a sulfur‐substituted carbazole‐based SAM forms Pb─S antibonding hybrid states at the buried perovskite interface, reconstructing the interfacial energetic structure and yielding a chemically reinforced hole‐selective contact. Density functional theory and spectroscopic analyses confirm the formation of Pb─S antibonding interactions with optimized interfacial energetics. This interfacial chemical reinforcement suppresses nonradiative recombination, relaxes residual lattice strain, and enables rapid hole extraction under operating conditions. Integrated into monolithic perovskite–silicon tandems, this strategy delivers certified power conversion efficiencies exceeding 33% together with markedly enhanced operational stability under maximum power point tracking.
High‐Entropy Lead‐Free Relaxor Ferroelectric Ceramic with Wide‐Temperature‐Range Self‐Powered X‐Ray Detection
ABSTRACT Sensitive and stable x‑ray detectors are essential for low‑dose medical diagnostics. Achieving wide‑temperature operation in materials remains a key challenge for enabling thermally stable, self‐powered x‑ray detection. Herein, a high‐entropy lead‐free relaxor ferroelectric ceramic, 0.85Bi 0.47 Na 0.47 Ba 0.06 TiO 3 ‐0.15Ca 0.7 Ho 0.2 Ti 0.75 Ta 0.2 O 3 (BNBT‐CHTT), is fabricated first. The unique entropy‐stabilized polar nanoregions (PNRs) endow the system with high resistivity and robust spontaneous polarization, underpinning exceptional self‐powered performance across a broad thermal window. Under 70 keV x‐ray irradiation, the detector exhibits excellent stability from 25°C to 185°C, delivering record‐high specific sensitivities of 1117.44–1223.55 µC Gy air −1 cm −2 , self‐powered sensitivities of 597.28–699.78 µC Gy air −1 cm −2 , and low detection limits of 38.7–160.6 nGy a i r s −1 . Notably, distortion‐free x‐ray imaging is demonstrated at 185°C under zero bias, validating the material's practical utility. This work highlights the potential of high‐entropy relaxor ferroelectrics to overcome key limitations of existing detectors and provides a robust platform for next‐generation, low‐power, wide‐temperature‐range x‐ray detection and imaging technologies.